The susceptibility of tumors to regress with CTLA-4 blockade was further shown to correlate with the immunogenicity of the tumor, and the response in poorly immunogenic tumors could be augmented by co-treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) vaccines [16,17]. The gene discussed is CTLA4; the disease is neoplasm.